Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Mantle-Cell 13Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 5Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Pyloric Stenosis, Hypertrophic 1Part1: Advanced B-cell Malignancies 1Neuritis 1Neoplasms 1Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Leukemia 1Hematologic Neoplasms 1Hematologic Diseases 1Glioblastoma 1Cardiovascular Diseases 1Anemia, Hemolytic, Autoimmune 1

Interventions

acalabrutinib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neuritis × acalabrutinib × Clear all
NCT05065554 2025-12-05

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡